News

AstraZeneca and Danaher announced on Friday the launch of a partnership focused on developing and marketing AI-based diagnostics to help clinicians identify patients best suited for precision medicine. Together, the companies will build a framework that speeds up the end-to-end process of bringing new diagnostics to market. As part of the collaboration, Danaher will support all phases of development across a range of diagnostic platforms. Working at Danaher's Center for Enabling Precision Medicine in the UK, the companies will initially focus on creating digital and computational pathology projects, as well as AI-assisted algorithms. The R&D hub was opened in 2024 to support faster, more efficient companion diagnostic development.